High-Throughput Screening (HTS) Market Size, Share and Growth Outlook, 2026

High-Throughput Screening (HTS) Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global High-Throughput Screening (HTS) Market size is forecast to increase from $34.39 Billion in 2026 to $75.89 Billion in 2034 at a CAGR of 10.4% between 2026 and 2034.

The High-Throughput Screening (HTS) market report provides detailed analysis and outlook of High-Throughput Screening (HTS) segments including By Product & Service (Instruments, Reagents, Kits & Consumables, Software & Informatics, HTS Services), By Technology (Ultra-high-throughput Screening, Cell-based Assays, Lab-on-a-chip & Microfluidics, Label-free Technologies, High-content Screening (HCS)), By Application (Target Identification & Validation, Primary & Secondary Screening, Toxicology & ADME, Stem Cell Research), By End-User (Pharmaceutical & Biotechnology Firms, Contract Research Organizations, Academic & Research Institutions) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

High-Throughput Screening (HTS) Industry Overview

Automation and Artificial Intelligence Are Transforming High-Throughput Screening Workflows

The high-throughput screening industry is advancing rapidly as pharmaceutical companies, biotechnology organizations, and research institutions increasingly adopt automated technologies to accelerate drug discovery and target identification. High-throughput screening platforms enable the rapid evaluation of thousands to millions of compounds, biological targets, and genetic interactions within compressed development timelines. Industry innovation is increasingly centered on artificial intelligence, machine learning, microfluidics, and cloud-connected informatics systems that improve screening efficiency, data quality, and experimental reproducibility. As the demand for precision therapeutics and biologics continues to grow, high-throughput screening technologies are becoming fundamental tools in modern pharmaceutical research and development.

Artificial Intelligence Enhances Phenotypic Screening Capabilities

A major trend within the high-throughput screening industry is the integration of artificial intelligence into automated screening platforms. PerkinElmer implemented a comprehensive technological upgrade across its cell-based imaging and screening portfolio, embedding advanced artificial intelligence and machine learning algorithms directly into image acquisition software. These capabilities allow automated laboratories to characterize intracellular phenotypic variations, monitor lead compound interactions, and evaluate drug toxicity profiles across extensive chemical libraries with minimal manual intervention. By automating image interpretation and biological pattern recognition, artificial intelligence is helping researchers accelerate hit identification, improve screening accuracy, and generate deeper insights from complex biological datasets.

Miniaturized Assay Platforms Improve Screening Efficiency

The increasing adoption of miniaturized screening technologies is enhancing productivity while reducing operational costs. Tecan Trading AG introduced next-generation assay automation systems specifically designed for high-throughput antibody screening and biologics discovery applications. The platform utilizes high-precision microfluidics and automated liquid handling technologies capable of managing sub-microliter assay volumes within 384-well and 1536-well plate formats. These innovations help biotechnology companies reduce reagent consumption, minimize consumable waste, and improve assay reproducibility. As biologics development becomes increasingly complex, miniaturized assay technologies are supporting more efficient experimentation while maintaining the precision required for advanced therapeutic discovery programs.

Cloud-Connected Informatics Strengthen Global Research Collaboration

Data management and computational integration are becoming critical components of the high-throughput screening ecosystem. Agilent Technologies expanded its digital informatics portfolio through cloud-connected software architectures that directly link functional genomic screening platforms with decentralized data analysis environments. The system automates data ingestion from CRISPR screening and target validation experiments, eliminating local computational bottlenecks and enabling seamless collaboration across geographically distributed research teams. Researchers can securely compare biological screening results with public multi-omics databases, accelerating target validation and biomarker discovery activities. The integration of cloud computing and automated informatics is helping pharmaceutical organizations streamline decision-making and enhance the scalability of global drug discovery operations.

High-Throughput Screening (HTS) Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global High-Throughput Screening (HTS) market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter/Molecular Devices), Revvity, Inc. (PerkinElmer), Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Tecan Group Ltd., Charles River Laboratories International, Inc., QIAGEN N.V., Corning Incorporated. The High-Throughput Screening (HTS) market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the High-Throughput Screening (HTS) industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth High-Throughput Screening (HTS) Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by High-Throughput Screening (HTS) companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional High-Throughput Screening (HTS) markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

High-Throughput Screening (HTS) Market Competitive Benchmarking and Company Analysis

Leading companies in High-Throughput Screening (HTS) industry include- Thermo Fisher Scientific Inc., Danaher Corporation (Beckman Coulter/Molecular Devices), Revvity, Inc. (PerkinElmer), Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Tecan Group Ltd., Charles River Laboratories International, Inc., QIAGEN N.V., Corning Incorporated. The High-Throughput Screening (HTS) market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US High-Throughput Screening (HTS) Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the High-Throughput Screening (HTS) market remains one of the strongest-performing segments in the country.
The US High-Throughput Screening (HTS) Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US High-Throughput Screening (HTS) market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across High-Throughput Screening (HTS) industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian High-Throughput Screening (HTS) markets

Canada's strong High-Throughput Screening (HTS) sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian High-Throughput Screening (HTS) market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany High-Throughput Screening (HTS) Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest High-Throughput Screening (HTS) market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of High-Throughput Screening (HTS) population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany High-Throughput Screening (HTS) industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the High-Throughput Screening (HTS) market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support High-Throughput Screening (HTS) sales through 2034

France High-Throughput Screening (HTS) companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK High-Throughput Screening (HTS) Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of High-Throughput Screening (HTS) distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China High-Throughput Screening (HTS) Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China High-Throughput Screening (HTS) market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of High-Throughput Screening (HTS) industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese High-Throughput Screening (HTS) industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India High-Throughput Screening (HTS) Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian High-Throughput Screening (HTS) market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil High-Throughput Screening (HTS) market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa High-Throughput Screening (HTS) Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

High-Throughput Screening (HTS) Market Segmentation

By Product & Service
Instruments
Reagents, Kits & Consumables
Software & Informatics
HTS Services
By Technology
Ultra-high-throughput Screening
Cell-based Assays
Lab-on-a-chip & Microfluidics
Label-free Technologies
High-content Screening (HCS)
By Application
Target Identification & Validation
Primary & Secondary Screening
Toxicology & ADME
Stem Cell Research
By End-User
Pharmaceutical & Biotechnology Firms
Contract Research Organizations
Academic & Research Institutions

Top Companies in High-Throughput Screening (HTS) Industry

Thermo Fisher Scientific Inc.
Danaher Corporation (Beckman Coulter/Molecular Devices)
Revvity, Inc. (PerkinElmer)
Agilent Technologies, Inc.
Merck KGaA
Bio-Rad Laboratories, Inc.
Tecan Group Ltd.
Charles River Laboratories International, Inc.
QIAGEN N.V.
Corning Incorporated

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025